Mumps vaccine and preparation thereof

• US 3,961,046 A
• Filed: 12/02/1974
• Issued: 06/01/1976
• Est. Priority Date: 12/02/1974
• Status: Expired due to Term

• Current Assignee: American Colloid Company (Minerals Technologies Incorporated)
• Original Assignee: American Colloid Company (Minerals Technologies Incorporated)
• Inventors: Cerini, Costantino Peter
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US05/528,752
• Time in Patent Office: 547 Days
• Field of Search: 195/1.3, 424/89
• US Class Current: 424/212.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/165 Mumps or measles virus
• CPC Class Codes: C12N 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

A non-pathogenic but antigenic live mumps virus useful in making mumps vaccine is produced by three serial passages through primary human amnion cell monolayers followed by one passage in embryonated chicken eggs and finally by from 8 through 28 serial passages in primary chick embryo tissue cells.

Claims

1. A mumps vaccine comprising:

A. as its essential ingredient an immunologically effective amount of an attenuated mumps virus characterized by

a. when injected into humans

i. being free of clinical manifestatins of the disease and

ii. invoking in man an antibody response to a virulent virus;

b. being capable of inducing its own replication in living cells; and

c. having been attenuated from virulent mumps virus by three serial passages in primary human amnionic cell monolayers at 34°

C. to 37°

C., followed by one passage in embryonated chicken eggs at 34°

C. to 37°

C., followed by replication in chick embryo tissue at 32°

C. to 37°

C. for from 8 through 28 passages; and

B. a stabilizer.

2. A vaccine of claim 1 wherein the stabilizer is sorbitol and N-Z amine NaK.

3. A freeze-dried mumps vaccine of claim 1.

4. A mumps vaccine comprising:

A. as its essential ingredient an immunologically effective amount of an attenuated mumps virus characterized by

a. when injected into humans

i. being free of clinical manifestations of the disease, and

ii. invoking in man an antibody response to a virulent virus;

b. being capable of inducing its own replication in living cells; and

c. having been attenuated from virulent mumps virus by three serial passages in primary human amnionic cell monolayers at 36°

C., followed by one passage in embryonated chicken eggs at 36°

C., followed by replication in chick embryo tissue at 36°

C. for from 8 through 23 passages; and

B. sorbitol and N-Z amine NaK as stabilizer.

5. A freeze-dried mumps vaccine of claim 4.

6. A process of preparing a live mumps virus useful as an antigen in a vaccine which will evoke in man an antibody response against a virulent mumps virus without causing the severe clinical manifestations of the disease which comprises growing the virulent virus by three serial passages in primary human amnionic cell monolayers at 34°

C. to 37°

C., followed by one passage in embryonated chicken eggs at 34°

C. to 37°

C., followed by replication in chick embryo tissue at 32°

C. to 37°

C. for from 8 through 28 passages.

7. A process of preparing a live mumps virus useful as an antigen in a vaccine which will evoke in man an antibody response against a virulent mumps virus without causing clinical manifestations of the disease which comprises growing the virulent virus by three serial passages in primary human amnionic cell monolayers at 36°

C., followed by one passage in embryonated chicken eggs at 36°

C., followed by replication in chick embryo tissue at 36°

C. for from 8 through 23 passages.